MeiraGTx Aktie - MGTX

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

7,75

Gebot

7,80

Fragen

8,20

Volumen

616.949

7,68 Tagesbereich 7,95

3,85 52-Wochen-Bereich 8,75

Marktkapitalisierung

611,126M

Handelsende

7,69

Handelsbeginn

7,72

Letzte Trade

500

7.75

(formt)

Letzter Handelszeitpunkt

Finanzvolumen

US$ 4.828.222

VWAP

7,826

Durchschnittliches Volumen (3 Mio.)

465.111

Ausgegebene Aktien

78.854.936

Dividendenrendite

Kurs-Gewinn-Verhältnis

-7,30

Gewinn pro Aktie (EPS)

-1,07

Erlöse

14,02M

Nettogewinn

-84,03M

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, United Kingdom, and Eu... MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, United Kingdom, and European Union. Mehr anzeigen

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.meiragtx.com

Hauptsitz

Grand Cayman, Cym

Gegründet

MeiraGTx Holdings PLC is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker MGTX. The last closing price for MeiraGTx was US$7,69. Over the last year, MeiraGTx shares have traded in a share price range of US$ 3,85 to US$ 8,75.

MeiraGTx currently has 78.854.936 shares in issue. The market capitalisation of MeiraGTx is US$606,39 million. MeiraGTx has a price to earnings ratio (PE ratio) of -7.30.

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to...

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint...

Form 4 - Statement of changes in beneficial ownership of securities

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited...

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (Nasdaq: MGTX), a...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.123	-1.5623015369	7.873	7.96	7.28	523241	7.62243482	CS
4	0.58	8.08926080893	7.17	8.75	5.77	753675	7.64776844	CS
12	1.82	30.6913996627	5.93	8.75	5.6	465111	7.16656881	CS
26	3.72	92.3076923077	4.03	8.75	3.968	378925	6.60479155	CS
52	1.38	21.6640502355	6.37	8.75	3.85	276072	5.98672747	CS
156	-6.22	-44.5239799571	13.97	15.16	3.49	215913	6.39981798	CS
260	-3.13	-28.7683823529	10.88	24.8948	3.49	190695	9.56012115	CS

MGTX - Frequently Asked Questions (FAQ)

What is the current MeiraGTx share price?

The current share price of MeiraGTx is US$ 7,75

How many MeiraGTx shares are in issue?

MeiraGTx has 78.854.936 shares in issue

What is the market cap of MeiraGTx?

The market capitalisation of MeiraGTx is USD 606,39M

What is the 1 year trading range for MeiraGTx share price?

MeiraGTx has traded in the range of US$ 3,85 to US$ 8,75 during the past year

What is the PE ratio of MeiraGTx?

The price to earnings ratio of MeiraGTx is -7,3

What is the cash to sales ratio of MeiraGTx?

The cash to sales ratio of MeiraGTx is 43,76

What is the reporting currency for MeiraGTx?

MeiraGTx reports financial results in USD

What is the latest annual turnover for MeiraGTx?

The latest annual turnover of MeiraGTx is USD 14,02M

What is the latest annual profit for MeiraGTx?

The latest annual profit of MeiraGTx is USD -84,03M

What is the registered address of MeiraGTx?

The registered address for MeiraGTx is 27 HOSPITAL ROAD, GEORGE TOWN, GRAND CAYMAN

What is the MeiraGTx website address?

The website address for MeiraGTx is www.meiragtx.com

Which industry sector does MeiraGTx operate in?

MeiraGTx operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
TNONTenon Medical Inc	US$ 3,82 (290,55%)	291,65M
GDHGGolden Heaven Group Holdings Ltd	US$ 3,7606 (91,87%)	33,35M
DATSDatChat Inc	US$ 3,78 (75,00%)	143,62M
RAYRaytech Holding Ltd	US$ 1,98 (52,31%)	15,19M
POAIPredictive Oncology Inc	US$ 1,6806 (50,73%)	152,85M
MURAMural Oncology PLC	US$ 1,48 (-61,36%)	4,04M
BACKIMAC Holdings Inc	US$ 0,19 (-55,02%)	6,29M
CNSPCNS Pharmaceuticals Inc	US$ 1,61 (-52,37%)	2,4M
WLGSWang and Lee Group Inc	US$ 0,433 (-42,34%)	14,2M
SGLYSingularity Future Technology Ltd	US$ 0,885786 (-40,55%)	1,33M
MULNMullen Automotive Inc	US$ 0,2377 (-7,08%)	418,4M
TNONTenon Medical Inc	US$ 3,82 (290,55%)	291,65M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 11,8507 (6,19%)	242,56M
NVDANVIDIA Corporation	US$ 120,69 (-0,59%)	167,46M
BONBon Natural Life Ltd	US$ 0,1615 (8,32%)	153,12M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

MeiraGTx Holdings PLC (MGTX) Börsenkurse

MeiraGTx Holdings PLC (MGTX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über MeiraGTx Holdings PLC

MGTX Neueste Nachrichten

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

MGTX - Frequently Asked Questions (FAQ)

Beweger

MGTX Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen